87 data "https:" "https:" "https:" "https:" "Grenoble INP Institute of Engineering" positions at UNIVERSITY OF SOUTHAMPTON
Sort by
Refine Your Search
-
engineered cytotoxic invariant Natural Killer T (iNKT) cells for precision targeting of paediatric cancer neoantigens. Building on strong preliminary data, it combines mechanistic and translational immunology
-
7 Apr 2026 Job Information Organisation/Company UNIVERSITY OF SOUTHAMPTON Research Field Computer science Engineering Mathematics Physics Researcher Profile Recognised Researcher (R2) First Stage
-
(m.kalkowski@soton.ac.uk ) Where to apply Website https://www.timeshighereducation.com/unijobs/listing/409452/research-fellow-in-… Requirements Additional Information Work Location(s) Number of offers
-
7 Apr 2026 Job Information Organisation/Company UNIVERSITY OF SOUTHAMPTON Research Field Computer science Physics Researcher Profile First Stage Researcher (R1) Application Deadline 20 Apr 2026 - 00
-
data. Develop and apply signal processing workflows for weak transient signals, long-term monitoring, feature extraction and statistical analysis. Support sound playback/stimulation protocols for plant
-
information on the group and BRC: https://www.southampton.ac.uk/medicine/about/staff/hmha.page and https://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Research/Facilities/NIHR-Southampton-Biomedical-Research
-
methods. It may also include quantitative data analysis. The post-holder will take a role in all stages of this process, from conceptualisation to data collection and analysis, as well as writing up and
-
28 Mar 2026 Job Information Organisation/Company UNIVERSITY OF SOUTHAMPTON Research Field Biological sciences Researcher Profile First Stage Researcher (R1) Application Deadline 3 May 2026 - 00:00
-
28 Mar 2026 Job Information Organisation/Company UNIVERSITY OF SOUTHAMPTON Research Field Engineering Physics Researcher Profile Recognised Researcher (R2) Established Researcher (R3) Application
-
invariant Natural Killer T (iNKT) cells for precision targeting of AML, an aggressive leukaemia with poor survival outcomes. Building on strong preliminary data, it combines mechanistic and translational